

Supplement dated and registered 1 December 2023 to the base prospectus approved by the Swedish Financial Supervisory Authority (the “**Swedish FSA**”) on 24 May 2023.

---

# NOBA

---

This supplement (Swedish FSA ref. no. 23-32571) (the “**Supplement**”) is a supplement to, and shall be read together with, NOBA Bank Group AB (publ)’s (the “**Company**”) base prospectus dated 24 May 2023 (Swedish FSA ref. no. 23-13518) and the pertaining supplementary prospectuses dated 26 May 2023 (Swedish FSA ref. no. 23-15830) and 13 September 2023 (Swedish FSA ref. no. 23-24230) (the “**Prospectus**”) and constitutes a supplement pursuant to Article 23 of Regulation (EU) 2017/1129 (the “**Prospectus Regulation**”). This Supplement was approved and registered by the Swedish FSA on 1 December 2023. Terms defined in the Prospectus shall have the same meaning when used in this Supplement. In case of conflict between this Supplement and the Prospectus or documents incorporated by reference into the Prospectus, this Supplement shall prevail. This supplement was made public on 1 December 2023 and is available on the Company’s website, [www.noba.bank](http://www.noba.bank) (other than the documents incorporated by reference, no information on such website is part of this Supplement or the Prospectus).

This Supplement has been prepared due to the publication of the Company’s interim report for the third quarter of 2023, which was published on the Company’s website on 17 November 2023.

At the time of publication of this Supplement, there are no outstanding offers to purchase or subscribe for transferable securities under the Prospectus and thus there is no right of revocation.

## **Amendments and supplements to the Prospectus**

On page 62, in the table titled “*Incorporation by reference*”, a new row shall be added with the following information:

---

<b>The Issuer’s interim report for the third quarter of 2023</b>	as regards the consolidated financial information on page <b>12</b> for income statement, page <b>16</b> for balance sheet, page <b>17</b> for cash flow statement, page <b>18</b> for changes in equity capital and pages <b>20-52</b> for notes.
( <a href="https://mb.cision.com/Main/7708/3877736/2436995.pdf">https://mb.cision.com/Main/7708/3877736/2436995.pdf</a> )	
<b>The Issuer’s base prospectus from 7 December 2021</b>	as regards the general terms and conditions and form of final terms on pages <b>23-45</b> .
( <a href="https://cdn.sanity.io/files/gkt7xx1k/noba_prod/8eb1d4289c3cc5e32ed964d312b1b714fac86aab.pdf">https://cdn.sanity.io/files/gkt7xx1k/noba_prod/8eb1d4289c3cc5e32ed964d312b1b714fac86aab.pdf</a> )	

---